Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM96 CAR-T in advanced colorectal cancer
NCT06718738Phase 1Recruiting
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Dec 2024
- Primary completion
- Aug 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IM96 in colorectal cancer (CRC), sponsored by Immunochina Pharmaceuticals. Primary endpoint: Incidence of Treatment Related Adverse Events at 28 days. Started Dec 2024; status: recruiting.
02
Drugs
IM96
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06718738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06718738.